Research programme: p38 MAP kinase inhibitors - Scios

Drug Profile

Research programme: p38 MAP kinase inhibitors - Scios

Alternative Names: SD-282

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Scios
  • Class Indoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Interleukin 1 beta modulators; P38 mitogen-activated protein kinase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Postmenopausal-osteoporosis in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top